A simple pharmacokinetic model to predict concentrations of metabolites of di-2-ethylhexyl phthalate, DEHP, in humans starting from intakes of DEHP was developed and applied. This model predicts serum and urine concentrations of five DEHP metabolites: MEHP, 5oxo-MEHP, 5OH-MEHP, 5cx-MEPP, and 2cx-MMHP. The model was calibrated using data from an individual who dosed himself with 48.5 mg DEHP, and then took blood and urine samples over a 44-h period. The calibrated model was then used in two applications: one on a second set of individuals whose exposure to DEHP was through PVC medical devices in a blood platelet donation procedure, and one on background exposures in the United States (US). Based on 2001/02 NHANES data, median US background urine concentrations of MEHP, 5OH-MEHP, and 5oxo-MEHP are 4.1, 20.1, and 14.0 mg/l, respectively. Creatine and urine volume-correction approaches were used to backcalculate an average daily dose of DEHP in the range of 0.6-2.2 mg/kg per day. A ''background cohort'' including 8 individuals and 57 complete days of urination were assumed to be exposed to1.5 mg/kg per day, spread out in equal doses of 0.3 mg/kg per day at 0900, 1200, 1500, 1800, and 2100 h. The average predicted urine concentrations were 4.6, 15.9, and 9.4 mg/l for MEHP, 5OH-MEHP, and 5oxo-MEHP. These are similar, but the two secondary metabolites are slightly lower than medians found in NHANES. This slight difference between the NHANES results and the background simulations could have been due to differences in metabolism between the individual who provided the calibration data (61-year-old Caucasian male) and the general US population. Another explanation evaluated was that urine concentrations further from the time of exposure may have larger disparities between MEHP and the two secondary metabolites as compared with concentrations measured closer to the time of exposure.
Introduction
Phthalates are diesters of phthalic acids, which are a class of industrial chemicals extensively used as softeners of plastics, solvents in perfumes, and additives to hairsprays, lubricants, and insect repellents. Di-2-ethylhexyl phthalate, or DEHP, is used primarily as a plasticizer for PVC and can therefore be found in a variety of products, such as floor or wall coverings, vinyl gloves, toys and child-care articles, materials that have contact with foods, medical devices, and numerous other uses (Kavlock et al., 2006) . Many commercially important phthalates have been identified as endocrine disruptors in rodent studies, modulating inter alia the endogenous production of fetal testicular testosterone causing functional and structural impairment of reproduction and development (Foster, 2005; Howdeshell et al., 2007; Mahood et al., 2007; Rider et al., 2008) . The parent diester phthalates rapidly hydrolyze to the monoesters and some are then further metabolized; all metabolites are excreted with urine and feces. Phthalates are excreted mostly within hours, with excretion completed within a day or two; half-lives in the body for parent and identified metabolites are in the range of hours. For phthalates with short alkyl chains, monoesters represent the major human metabolite, but in the case of phthalates with long alkyl chains, including DEHP, di-isonyl phthalate (DINP), and diisodecyl phthalate (DIDP), the monoesters are further metabolized via o-, o-1, and b-oxidations of the alkyl chain (ATSDR, 2002; Koch et al., 2006; Silva et al., 2006 Silva et al., , 2007 Wittassek et al., 2007a, b) .
The routes whereby people become exposed are not yet fully understood. Phthalates leach, volatilize, or otherwise disassociate from the consumer products to impact environmental and exposure media including food, air, house dust, soil, and water. Exposure assessments have included consideration of food and water, dermal contact (personal care products, toys, textiles, gloves, paints/adhesives, and particles), and inhalation (indoor/outdoor air, hair/paint sprays). Wormuth et al. (2006) conducted a comprehensive exposure assessment considering these pathways for Europeans for infants, toddlers, teenagers, and adults (male and female teenagers and adults). They used exposure media concentrations where they were available, and this often meant using data from countries outside of Europe and from studies having been conducted sometimes in the past decades. For example, the food data came from Germany, United Kingdom, and Japan and were available from a large list of products ranging from pasta to dairy to meats to fruits to beverages. Dust data were from Germany, and soil data were from China. Data on personal care product (PCP) concentrations were from the Cosmetic Ingredient Review (http://www.cir-safety.org/). Exposure models and assumptions were also determined from a diverse range of literature, with varying degrees of certainty. With this range and diversity, median exposures were quantified and they were highest for DEHP, between 1 and 5 mg/kg per day for children, teens, and adults, and they were also above 1 mg/kg per day for diethyl phthalate (DEP) but were between 0.1 and 1.0 mg/kg per day for dimethyl phthalate (DMP), diisobutyl phthalate (DiBP), di-n-butyl phthalate (DnBP), benzylbutyl phthalate (BBzP), and less than 0.1 mg/kg per day for DINP and DIDP. Exposures were always higher for infants, getting near or above 10 mg/kg per day for DEP and DEHP. In general, ingestion of food dominated for DEHP, personal care products dominated for DEP, and inhalation pathways dominated for DMP. A mixture of all pathways contributed to DnBP exposure.
Similar exposure studies have not been conducted for the United States (US). ATSDR (2002) , for example, discussed pathways on a qualitative basis in their Toxicological Profile for DEHP, although they provided several references on measurements in exposure media. Meek and Chan (1994) quantified pathways of exposure for DEHP for Canadians in the 1980s. For adults, the total estimated intake was 5.8 mg/ kg per day, dominated by food at 4.9 mg/kg per day. They also quantified indoor air exposures, drinking water exposures, and soil exposures.
Instead of characterizing exposure via a pathway analysis as did Wormuth et al. (2006) , other exposure assessments have focused on the measurement of phthalate metabolites in urine. Parent phthalates are not measured in urine because of the known rapid metabolism to the monoester and other secondary metabolites, and also the concern for parent phthalate contamination of laboratory equipment. Most studies have characterized exposure by measuring the monoester metabolites of diester parent phthalates. For DEHP, this metabolite is mono-(2-ethylhexyl) phthalate, or MEHP. However, Barr et al. (2003) and Koch et al. (2003a, b) advocated the analysis of the additional oxidized DEHP metabolites, mono-(2-ethyl-5-oxohexyl) phthalate, abbreviated as 5oxo-MEHP, and mono-(2-ethyl-5-hydroxyhexyl) phthalate, or 5OH-MEHP. Their justification is that the monoester metabolite of the higher molecular weight phthalates such as DEHP comprise a small amount of the overall metabolism of the phthalate to the point that possibly the monoester would not be detected in urine, whereas the additional metabolites such as 5oxo-MEHP or 5OH-MEHP have been found at up to four times the concentration of MEHP. MEHP, as the first metabolite created, disappears first from the body, whereas the secondary metabolites might continue to show up even after MEHP is not detected in the urine. Beginning in the 2001/02 sampling period and more currently, the 2003/04 period of the National Health and Nutritional Examination Survey (NHANES; CDC, 2005), these oxidized metabolites were included in the DEHP exposure measurements. Koch et al. (2003a Koch et al. ( , b, 2004 Koch et al. ( , 2005a have also characterized exposures of German populations using measurements of the three DEHP metabolites: MEHP, 5oxo-MEHP, and 5OH-MEHP. In the study which is used to calibrate the model of this paper, they also measure two additional metabolites: mono (2-ethyl-5-carboxypentyl) phthalate, or 5cx-MEPP, and mono(2-(carboxymethyl)hexyl) phthalate, or 2cx-MMHP (Koch et al., 2005a) . These metabolites have even longer half-lives of elimination than the above-oxidized metabolites and, furthermore, 5cx-MEPP has been shown to be the major urinary metabolite of DEHP (Silva et al., 2006) .
However, up to now, most exposure studies on phthalates in urine have focused on the simple monoester metabolites, and for the US, the best characterization of background exposures comes from NHANES (Blount et al., 2000; Silva et al., 2004; CDC, 2005) . Blount et al. (2000) obtained urine samples from 289 subjects randomly selected from the full set of NHANES III, 1988-94 , and measured seven phthalate monoester metabolites including monoethylphthalate (MEP; monoester of DEP), mono-n-butylphthalate (MnBP; monoester of DnBP), monobenzylphthalate (MBzP; monoester of BBzP), and MEHP. The geometric mean concentrations in mg/l urine (mg/g creatinine in parenthesis) for these metabolites were: MEPF345 (345), MnBPF41.5 (36.9), MBzPF22.6 (20.2), and MEHPF3.5 (3.0) Silva et al. (2004) measured urine samples of 3094 individuals, or a 1/3 subset of the NHANES 1999-2000 full set of 9282 people. The geometric mean of all individuals' (and all were greater than 6 years old) concentrations in mg/l (mg/g creatinine) of the four most frequently detected were: MEPF179 (163), MnBPF24.6 (22.4), MBzPF15.3 (14.0), and MEHPF 3.43 (3.12) . As seen, the MEHP concentrations were fairly similar in both cohorts at about 3.5 mg/l urine, and about 3.1 mg/g creatinine. It has to be noted that simple comparisons of the excreted monoester metabolite concentrations do not always translate to similar relationships of actual exposures to the parent phthalates. For example, although MEP and MnBP are the major urinary metabolites (approximately 70% of an oral dose) of the parent phthalates DEP and DnBP, MEHP is only a minor urinary metabolite (approximately 10% of an oral DEHP dose). The CDC report, Third National Report on Human Exposure to Environmental Chemicals (CDC, 2005) , contains extrapolated results from 2782 individuals sampled in 2001/02 for MEHP and, as noted earlier, two key metabolites, 5OH-MEHP and 5oxo-MEHP. The medians (urine in mg/l and creatinine-corrected in mg/g in parenthesis) for all individuals above 6 years old for MEHP, 5OH-MEHP, and 5oxo-MEHP were 4.1 (3.9), 20.1 (16.6), and 14.0 (11.2), respectively. These data will be used later in an evaluation of background exposures using the model of this paper.
It is noted that these results are expressed not only in concentration terms but also normalized to urinary creatinine. Through this normalization, one can estimate the daily cumulative excretion of the metabolite from concentrations in spot urine samples. Based on the work of Koch et al. (2005a) , the relationship between the metabolites (MEHP and/or oxidized metabolites) and the parent DEHP are known, and this allows for an estimation of the daily exposure to DEHP. The methods to make this calculation will be described later, but they have been used by David (2000) and Kohn et al. (2000) in conjunction with the NHANES data (phthalate monoesters) by Blount et al. (2000) to estimate daily exposures to DEHP of 0.6 mg/kg per day (David, 2000) and 0.7 mg/kg per day (Kohn et al., 2000) . Koch et al. (2003a) introduced the oxidized DEHP metabolites for daily intake estimations and Wittassek et al. (2007a) estimated DEHP exposures based on the three metabolites MEHP, 5OH-MEHP, 5oxo-MEHP in first morning voids from a population of 239 German children (GerES: German Environmental Survey). They found a median daily DEHP intake of 4.3 mg/kg per day for children. In 24-h urine samples taken from the German Environmental Specimen Bank for Human Tissues (ESBHum), which were collected from 634 German students between 1988 , Wittassek et al. (2007b estimated a median DEHP intake (again based on the three DEHP metabolites) of 3.5 mg/kg per day.
Pharmacokinetic (PK) modeling has not been used to any extent to study exposure to phthalates. Cahill et al. (2003) attempted to model human exposure to DEHP and DBP (along with styrene and trichloroethene) using a generalized physiologically-based pharmacokinetic model but was finding the simulation problematic for DEHP. They found that the log Kow of DEHP, provided as 7.75, would result in highly efficient absorption of DEHP, whereas animal experiments suggest poor absorption for DEHP. They also noted a lack of data to assign reaction rate constants for the primary metabolite, MEHP. Besides this effort, only some work in the 1980s on a pharmacokinetic model for uptake and disposition of DEHP in sheepsheads minnow (Karara and Hayton, 1984) , and a physiologically-based pharmacokinetic model for DEHP in rats (Keys et al., 1999) could be found.
The forward-based PK approach advocated in this paper is clearly distinct from the backcalculation estimation procedures used to characterize daily intakes of phthalates based on phthalate metabolite and creatinine concentrations in urine that were described earlier. PK models require as independent inputs a dose schedule of a contaminant F times, amounts, method of entry into the body, and so on F and the dependent model predictions are the concentrations in body tissues (e.g., lipids, organs, blood, urine). They have the capability of studying the temporal variability of tissue concentration in response to varying dose, which for phthalates translates to variability over the course of minutes to hours. In contrast, the backcalculation approaches start with the urine concentration of phthalate and creatinine, and with simple steady state assumptions, estimate a daily dose that corresponds to the spot urine measurements in a onestep backcalculation procedure.
The pharmacokinetic model developed in this paper can be characterized as a ''simple'' pharmacokinetic model, in that it considers a minimal amount of body compartments, rate constants, and other required inputs. Similar PK models have been used successfully to study exposures to dioxins (Lorber, 2002; Aylward et al., 2005) , PBDEs (Lorber, 2008a) , perfluorinated compounds including PFOS and PFOA (Washburn et al., 2005; Trudel et al., 2008) , and recently to perchlorate (Lorber, 2008b) . These simple models require a minimal set of input parameters; specifically, parameters describing overall dissipation or loss from the body or tissue being modeled, and parameters describing the volume of mixing (in blood, urine, or body fat) are all that are required. In contrast, physiologically-based pharmacokinetic (PBPK) models require parameterization of numerous metabolism rate constants or transfer coefficients between body tissues and organs. The simple models do not provide information on target organ dose and cannot address potential health impacts. However, with the proliferation of biomonitoring studies (like NHANES in the US and GerES in Germany) these simple models provide a valuable means to tie external dose to measurements in body fluids/tissues. Because of this capability, patterns of external exposure can be studied effectively with minimal and manageable PK modeling requirements. Temporal trends, such as trends throughout decades as in dioxin exposure (Lorber, 2002) or over the course of a day as in perchlorate (Lorber, 2008b) or DEHP, are effectively studied. The structure and approach to studying DEHP in this paper can be easily extended to other phthalates with the proper data.
Methods and model applications

Structure of the model
This paper develops a simple pharmacokinetic model to estimate the exposure of Americans in the US to DEHP. Describing it as a ''pharmacokinetic'' model may be generous, as it is a mathematical modeling structure that simulates serum and urine concentrations using a general first-order dissipation model along with routing assumptions from parent to metabolite and to the bladder for excretion via urination. The model requires an empirical ''volume of distribution'' in serum to predict serum concentrations, along with first-order dissipation rates for parent and metabolite, ''fractions'' describing the routing of dissipating parent or metabolite to other metabolites, to the bladder, or elsewhere (i.e., not modeled further), and inputs of urine volumes and times of urination to simulate urine concentrations. It neglects physiological processes in the body pertinent to phthalates including any routing through the lungs, gastrointestinal system, liver, kidney, and other organs. The approach is only possible when detailed human data are provided on which the model is calibrated. The model structure is first defined and then calibrated using data from an individual who dosed himself orally with DEHP. Blood samples during the first 8 h after administration and urine samples over the next two days provided data upon which to calibrate the model. The model is then applied to a second data set on 12 individuals whose exposure was by intravenous platelet donation using disposable PVC medical devices that introduced DEHP directly into the bloodstream. A third model exercise entails simulation of background exposures of Americans to DEHP. A backcalculated DEHP daily dose is applied in the model in a forward simulation to predict urine concentrations of MEHP, 5OH-MEHP, and 5oxo-MEHP. As well, the variability of urine concentrations over the course of a day in this background scenario is studied with the modeling structure. Koch et al. (2005a) provide a description of the internal metabolism of DEHP, synthesized from several studies of DEHP metabolism in the 1980s and 1990s. This description is shown in Figure 1 . Shaded in that figure are the metabolites that were measured in urine of a single individual who exposed himself to a high level of DEHP. These same five metabolites are simulated in the model structure of this paper, and the data from this individual as described in Koch et al. (2005a) are used to calibrate the model (described below). An administered dose of DEHP is assumed to instantaneously mix into the blood serum. This dose metabolizes to MEHP, which in turn metabolizes in part to 5OH-MEHP, 5cx-MEPP, and 2cx-MMHP. The metabolite 5OH-MEHP is then modeled to metabolize in part to 5oxo-MEHP.
Serum concentrations of the parent as well as the metabolites are calculated as the masses in the ''reservoir'' of each parent/metabolite at a given point in time divided by a ''mixing volume of serum.'' This mixing volume (typically abbreviated VM for volume of mixing) is a constant and a calibrated parameter; it does not have a physiological definition such as the volume of serum circulating at any given point in time, which is about 2.5 l for an adult (or 5 l of whole blood coupled with the assumption that blood serum is about 50% of whole blood). It might be pointed out that for persistent lipophilic organic contaminants, such as dioxins or polybrominated diphenyl ethers (PBDEs), this mixing volume does have a physiological definition and is the volume of lipids in the body. This volume is calculated as (weight of individual) Â (lipid fraction of individual). In the general model of this paper and for other contaminants that mix in serum, the VM is considered to be the volume of serum that best duplicates appropriate contaminant concentration data in a calibration of the model. It could be much larger than the volume of serum in the body at any time, or smaller. For example, it could be larger if the modeler assumes a full instantaneous deposition into the serum, while physiologically saturable processes may be occurring such that mixing may occur over a long period of timeFthe antithesis of instantaneous mixing. Alternately, the VM could be lower than the standing volume of serum in the body, as in the case of the contaminant distributing throughout the body to other organs such that only a small amount of the dose in fact remains in the serum. Often in using this modeling approach, these subtleties are not fully understood; the VM is simply calibrated using the available data, with the modeler then left to consider and justify the physiological underpinnings of the calibrated volume if that is useful. Another consideration for the modeling of DEHP metabolites is whether each metabolite has a separate VM. Most applications of this approach address only one contaminant, so the issue of choosing VMs for different metabolites is not necessary. Although there likely is not a strict physiological or technical reason to do so, it will be assumed in this paper that the mixing volume is the same value for all metabolites.
Metabolites dissipate from the ''serum reservoir'' assuming a first-order rate of dissipation. These rates of dissipation, given as ''k'' values typically, are overall rates of elimination, whether that elimination is active transport out of the reservoir or metabolism while still in the reservoir. They are calculated as the ratio of, 0.693/half-life, where the half-life is in units of hours in this application. For purposes of modeling, the amount dissipating out of the metabolite-specific reservoir is assumed to be available to be converted to another metabolite (and hence remain in the general serum reservoir, although now added to the amount of the other metabolite already residing in the serum reservoir), transported to the ''bladder'' as the unmetabolized compound, or to go elsewhere not modeled. The parameter describing these fates is termed the ''f'' value in this model. The f values are fractions that describe what part of the dissipating mass goes to either another metabolite serum reservoir or the general bladder reservoir. These f values are not molar fractions but are simply mass fractions that maintain the mass from reservoir to reservoir. The summation of f values for a dissipating metabolite does not necessarily add to 1.0; by definition, it cannot be greater than 1.0. As seen in Figure 1 , metabolites other than those modeled here are produced, and all metabolites are either excreted in urine or feces. The loss via feces is not considered here. The mass of each metabolite in the ''bladder reservoir'' is fully emptied with each urination.
The final structure of the model is displayed in Figure 2 . The calibrated rates of dissipation and the fractions describing the fate of dissipating metabolites are also shown. The calibration exercise is described in the next section. The structure is input into an Excel spreadsheet using a 15-min time step. Intake doses of DEHP are instantaneously mixed into an initial reservoir of serum, and metabolites begin showing up at the first 15-min time step. In addition to times and amounts of intake doses of DEHP, the times and volumes of urination are specified as inputs to the model. Koch et al. (2005a) describe the dosing of the senior author of their study with 48.5 mg of DEHP (lesser doses were also administered at different times, but detailed data on the concentrations of these amounts were not provided). The individual is male, age 61, and weighing 75 kg, and he selfadministered the dose by consuming the DEHP mixed with butter in buttered toast. Data taken from this individual included analysis of four samples of blood serum during the first 8 h (time specified) and 24 urine samples (time and volume specified) over 44 h after exposure. Each sample included measurements of five metabolites: MEHP, 5OH-MEHP, 5oxo-MEHP, 5cx-MEPP, and 2cx-MMHP. The data, generally described and graphed in Koch et al. (2005a) , were retrieved by Koch (a co-author on this paper) as precise quantities for use in this calibration.
Calibration of the model
The model was calibrated so that predicted serum concentrations and urine concentrations acceptably matched measurements. There was no rigorous algorithm used to assign the key model parameters, ''k'' and ''f''. Rather, a simple trail-and-error approach, in conjunction with known toxicokinetics and the data from the dosed individual, were brought into the calibration process. Specifically, the structure of the model shown in Figure 2 was based on the metabolic pathways shown in Figure 1 . This included, for example, the fact that an intake dose of DEHP converted completely to MEHP and not to any of the other metabolites. Key information from the observed data set assisted in the calibration. For example, the individual ingested 48.5 mg of DEHP, and the mass of all metabolites excreted over the 44 h afterwards when urine samples were taken totaled 27.4 mg, with individual metabolite masses ranging from 2.1 mg for 2cx-MMHP to 9.0 mg for 5OH-MEHP. The fraction of the initial dose of DEHP that became 5OH-MEHP should be near 0.19 (9/48.5), therefore, based on this data. In essence, the final fractions, f, of the intake dose delivered to the bladder as the five metabolites to be excreted were known from the data. Finally, the rate at which the metabolite formed and then dissipated from the serum reservoir is surmised from the serum data, and this information was used to establish k values in the calibration. There was not a rigorous goodness-of-fit algorithm that was used to establish the final values of the parameters. It is not clear that a rigorous quantitative method would lead to a better set of parameters than were developed through trialand-error and best judgment. For example, an ''optimized'' set of parameters might have led to a better match between serum concentration predictions and measurements but a less favorable match of urine concentrations. Parameter values were assigned with a goal of duplicating key trends in the data, such as the rapid decline of blood concentrations, the magnitude of high urine concentrations and when these high concentrations occurred, and finally the total mass of metabolite excreted in urine.
The final set of calibrated rates of dissipation, k, and fractions, f, are shown in Figure 2 . Not shown here was the calibrated volume of distribution. This parameter was calibrated to a value of 0.1 l/kg, which translates to a volume of about 7 l for an adult weighing 70 kg. This is about three times the standing volume of serum in an individual, which is about 2.5 l. As seen in Figure 2 , a rapid (k ¼ 2.77 h À1 that translates to a half-life of 15 min) and complete (f ¼ 1.0) transformation of DEHP to the monoester, MEHP, is implied. No DEHP was excreted in urine, according to this calibration. Other key observations from this calibration include (1) about 54% of the mass of DEHP is eventually excreted in urine as the sum of the masses of the five metabolites (calculated by tracking and adding the f fractions in Figure 2 ). As noted earlier, this is not a coincidence because the model was ''calibrated'' to arrive at this result; and (2) 2cx-MMHP dissipates most slowly out of the blood reservoir of all the metabolites, with a k of 0.07 h À1 (half-life of about 10 h). This actually translates to a build-up of 2cx-MMHP in the serum over time, unlike other metabolites that mostly dissipate from the blood reservoir over the course of the two days of the study. The results of the serum concentration calibration are provided in Figure 3 , which compares the predicted concentrations shown in solid lines to the four points of metabolite measurement, provided as squares or diamonds. One observation is that the general trend of decline appears reasonably well captured for the four metabolites that decline rapidly over the first 8 h. In contrast, the concentration of 2cx-MMHP appears reasonably steady over the 4 h as evidenced by the similarity in serum concentrations for the four time periods, and this trend was duplicated mainly by the selection of the slow rate of dissipation from this compartment, as noted above. It appears as though only the concentration of 5OH-MEHP may not have been satisfactorily captured by this modelFthe predictions were consistently higher than the measurements, although the trends in 5OH-MEHP urine concentrations and mass excreted were well captured. This suggests that the model was clearing 5OH-MEHP from the serum reservoir adequately, just not capturing concentrations in an appropriate manner. It was noted that all metabolites had the same VM, and perhaps this selection of VM for 5OH-MEHP was not appropriate, for some reason. A higher VM, say 0.2 l/kg instead of 0.1 l/kg, would have resulted in a better match of Simple pharmacokinetic model to characterize exposure of Americans to DEHP Lorber et al. predicted and observed serum concentrations, but as noted above, it was assumed that the VM should be the same for all metabolites. Figure 4 shows the trends in predicted (diamonds connected by solid lines) versus measured (shown as squares) urine concentrations. It is seen that for all metabolites, the magnitude of the maximum concentration, the time of the maximum concentration, and the rate of decline of the concentrations are all well captured in this calibration, with some clarifications and observations. There is a discrepancy in the concentration of the first MEHP data point: a concentration of 2.6 mg/l of MEHP was measured in the first urination, whereas the model predicted a concentration of 6.1 mg/l. This concentration was partly driven by a very low volume of urineFthis first urination had a volume of 0.09 l, which was among the lowest of the 24 urination events over the 44 h of measurement. Other predictions for the first urination event matched observations much better than MEHP. The observed urine concentrations of 5OH-MEHP, 5oxo-MEHP, and 5cx-MEPP appear to decline after the maximum a little more quickly than was modeled, but ultimately the observation of very low to non-existent concentrations by 14 h was captured in the modeling for all metabolites except 2cx-MMHP. Like for blood, the slightly different trend of continuing stable concentrations of 2cx-MMHP continuing through the 44 h was captured by the model's slow rate of dissipation out of the serum reservoir to the bladder for excretion. Figure 5 shows the cumulative mass excreted over the 44 h. It is seen that the trends in cumulative mass excreted of MEHP, 5oxo-MEHP, and 2cx-MMHP are very well captured. Both the measured and modeled accumulated masses appear to flatten out as the concentrations and excretions both approach zero. Because of the first-order dissipation algorithm, the same trend of a flattening out of excretion occurs for the modeled accumulation of 5OH-MEHP and 5cx-MEPP. However, the data suggest continuing low excretions through the 44 h of the measurement for these last two metabolites. Koch et al. (2005a, b) observe this bi-phasic trend in the data: a rapid decline in excretions within even the first 8 h after exposure, followed by a slower but continuing excretion over the next several hours. For 5OH-MEHP and 5cx-MEPP, this bi-phasic pattern is clear. For example, the observed concentration of 5OH-MEHP is between 0.05 and 0.1 mg/l (with one measurement at 0.34 mg/l) in seven urination events after 31 h, but the model simulates urine concentrations less than 0.001 mg/l for those seven events. Although these measurements at around 0.1 mg/l are much less than the maximum observed at between 5 and 10 mg/l for the first 8 h of excretions, they continue nonetheless and this was not captured by the model.
A decision not to attempt a bi-phasic modeling approach was made for this study. The capability of capturing the maximum observed concentrations (both timing and amounts), the primary declining trend in concentrations within the first several hours after exposure (for both serum and urine), and the total mass excreted were the most important objectives. Also, when applying the model for multiple exposures, as will be done in a background exercise described later, it would be very cumbersome to attempt to track each exposure to duplicate a bi-phasic loss trend.
Model applicationFblood donors
Data for an independent application of the model came from healthy individuals who volunteered to undergo apheresis procedures to donate blood components. Use of disposable medical products containing DEHP is necessary for this procedure, and this can result in exposure to DEHP. Koch et al. (2005b) sampled 18 individuals undergoing this procedure, including 6 plasma donors, 6 discontinuous flow platelet donors, and 6 continuous flow platelet donors, along with 5 controls. Three DEHP metabolites, MEHP, 5OH-MEHP, and 5oxo-MEHP, were measured in urine samples taken before the procedure (to get a baseline measurement) and for all urinations over the next 24 h. It was found that the individuals donating plasma did not have elevations of the DEHP metabolites in comparison to the controls (probably because the DEHP was enriched in the lipophilic plasma itself, which was not returned to the donor), but the 12 platelet donors clearly had elevations in their urinations, with a declining pattern similar to that seen in the single individual who orally dosed himself with DEHP, as described earlier. Raw data for these 12 individuals were retrieved by Koch and used in a model application for this paper. All model parameters remained unchanged from their calibrated values, and predicted concentrations of the three metabolites were compared with measurements. Over the 12 individuals, there were 93 urination events during the 24 h following the treatment in which these comparisons were made.
Unlike the calibration exercise, the initial dose to which they were exposed was not known, so it had to be calculated externally. This was done by Koch et al. (2005b) , who used this equation:
where MA metabolites is the molar amount of the three metabolites excreted over 24 h for each of the individuals, F ue is the urinary excretion ratio of the metabolites on a molar basis, and MW DEHP is the molecular weight of DEHP, which is 390 g/mol. Koch et al. (2005b) calculated an F ue of 0.46 based on their earlier study of the single individual (Koch et al., 2005a) ; these data were used to calibrate the model in this study. That is, after 24 h of their earlier experiment, 46% of the total administered DEHP was accounted for in the sum of the three metabolites in urine, on a molar basis. Using Eq. (1), they calculated the dose from each individual in the study. The average calculated dose of DEHP from the six continuous platelet donors was 2.1 mg, and the average dose from the six discontinuous flow platelet donors was 1.2 mg. This compares to 48.5 mg from the individual who dosed himself in the calibration exercise, and to about 0.4 mg from the set of controls and the plasma donors of their study. The individual doses were directly input into the model in simulations of each of the 12 individuals. Further, the donation procedure took about an hour, so the total DEHP dose was split into four equal doses, 1/4 of the total each, with the first exposure at absolute time ''0'' and then three more at 15 min intervals. Individuals in the experiment were asked to provide an initial urination after the procedure. This first urination event was termed the ''0'' time event within the data set, although it occurred 20-30 min after the procedure ended because the donors needed time to recover after the procedure, to dress, to complete paperwork, and so on. Because of this, the first urination was assumed to occur 0.5 h after the procedure ended and 1.5 h after the initial exposure. For purposes of this model application, exposures began essentially at À1.0 h, and the first urination occurred at þ 0.5 h, with all subsequent urinations characterized in terms of time after the procedure ended. For example, a urination at 6 h corresponds to the urination that occurred 6 h after the procedure ended and 5.5 h after the initial time ''0'' urination.
The results of this model application are shown in Table 1 and Figure 6 . As seen in Table 1 , the model very accurately predicted the average total mass of MEHP excreted in urine for both cohorts. However, the model underpredicted 5oxo-MEHP and overpredicted 5OH-MEHP in both cohorts. On a total mass basis (summing the mass of the three metabolites), the model predicted essentially the same amount of metabolite, 0.50 and 0.26 mg for the continuous and discontinuous cohort, respectively, as was measured, 0.51 and 0.26 mg for both cohorts. This is likely not a coincidence physiologically, that is, the general pathway and processes governing the metabolism of DEHP for the single individual in the calibration study who exposed himself with an oral dose of DEHP are likely the same pathway/processes at play for the individuals exposed via the platelet donation devices. For some reason, possibly the fact that the platelet donors were intravenously exposed while the single individual was orally exposed, the rate of dissipation of MEHP and the fractions determining the rate of formation of 5oxo-MEHP and 5OH-MEHP are different for these donors as compared with the single individual. If not because of the difference in DEHP administration, the difference could possibly be age relatedFthe single individual orally exposed was 61 years old, whereas the 12 donors ranged in age from 22 to 63 years, with 2 donors at 63 years of age, but the other 10 at under 40 years of age. The possible influence of age on metabolism of DEHP is discussed later in the section on background simulations.
Predicted and observed metabolite concentrations in urine were also compared. The averages over 2-h time steps (where again time 0 is counted as the time when the procedure stopped and the initial urination requested from the donors is assumed to occur at 0.5 h) are displayed in Figure 6 . Both the measured and modeled average metabolite urine concentration showed that peaks occurred 4-6 h from the end of exposure for the continuous exposure and 2-4 h from the end of exposure for the discontinuous exposure. The model reasonably predicted the magnitude of these peaks, as seen in Figure 6 . These results suggest that there was more rapid formation of 5OH-MEHP and 5oxo-MEHP than was modeled: the observed concentrations are always higher than the predicted concentrations for the 0-2 h time frame, particularly for the individuals in the continuous procedure.
Model applicationFbackground exposures
Although possibly an esoterically interesting exercise, the real value of this predictive model that takes intake dose of DEHP and predicts DEHP metabolite concentrations in blood serum and urine is its application to real world issues. For phthalates as well as a host of contaminants, a real world issue is background exposures. Prior to 2000, the simple monoester metabolites of the phthalates (e.g., MEHP for DEHP) have been utilized for exposure assessments. However, the NHANES data for 2001/02 and 2003/04 also measured two additional DEHP metabolites, 5OH-MEHP and 5oxo-MEHP. This background exercise will look at all three metabolites. The approach to study DEHP exposures using these metabolite urine concentrations with the model is as follows. First, simple procedures to take NHANES concentrations of MEHP urine concentrations are used to backcalculate possible exposures to DEHP. From these, a final value of a total daily background intake dose of DEHP is developed. A background exposure scenario is developed F times and masses of DEHP intake over the course of a day F and this scenario is applied to a cohort of individuals whose times and volumes of urination are known and provided as input. Urine concentrations of MEHP, 5OH-MEHP, and 5oxo-MEHP are predicted, and these are compared with the NHANES measurements of these three metabolites. If these predicted concentrations match NHANES concentrations, then a good measure of confidence is gained for the estimate of background intake dose of DEHP: it was backcalculated using empirical creatininebased or urine volume-based models, and when using it in a forward PK model, it was able to reproduce measured urine concentrations. Assuming this occurs, the model results will be examined further to comment on the daily temporal variability of urine concentrations of the metabolites. As described in the introduction, three studies on NHANES data (Blount et al., 2000; Silva et al., 2004; CDC, 2005) arrived at similar geometric mean MEHP urine concentration of about 3.5 mg/l MEHP and 3.0 mg/g creatine. Only one of the data sets included all three metabolites, and the final median concentrations from the 2001/02 NHANES data sets will be used. The NHANES data from 2003/04 also includes these metabolites, but the results from this sampling, while available publicly as individual results, have not been extrapolated to the United States as of this time. The results used from NHANES 2001/02 are the median concentrations extrapolated to all individuals in the United States over the age of 6 for MEHP, 5OH-MEHP, and 5oxo-MEHP. These medians are 4.1, 20.1, and 14.0 mg/l, respectively.
In a study of the exposure of the general population to DEHP, David (2000) and later Wittassek et al. (2007a) provide this generalized equation to backcalculate intake dose from urinary excretions of the first primary monoester phthalate metabolite:
where DI is the daily intake in mg/kg per day, UE is the phthalate metabolite in mg/g creatinine, CE is the daily creatinine excretion normalized to body weight, mg/kg per day, F ue is the molar fraction of the urinary excreted metabolite in relation to the ingested diester (fraction), 1000 mg/g is the units conversion factor, MW d is the molecular weight of the diester phthalate, and MW m is the molecular weight of the monoester metabolite. Values of these factors for DEHP intake calculation used here include male and female UE as 3.32 (male) and 4.43 (female) mg/g creatinine from CDC (2005), male and female CE as 23 and 18 mg/kg/day as provided in Kohn et al. (2000) , MW d as 390 g/mole, MW m as 278 g/mole, and finally, F ue calculated as 0.073 from the calibration data set with MEHP excretion as 2.54 mg and DEHP ingestion as 48.5 (specifically, [(2.54/278)/(48.5/390)]. Substitution of these values into Eq. (2) yields intakes of DEHP as 2.04 mg/kg per day for males and 1.53 mg/kg per day for females. Wittassek et al. (2007a, b) used this second empirical urine volume-based approach to estimate DEHP intake based on concentrations of DEHP metabolites in urine:
where DI is the daily intake in mg/kg/day, UC is the molar phthalate metabolite concentration in urine in moles/l, UV is the total daily urinary volume normalized to body weight, l/kg per day, F ue and MW d as defined earlier. F ue for MEHP is calculated above as 0.073. The concentration of MEHP is 4.30 mg/l for males and 4.10 mg/l for females (CDC, 2005) , so given that a mole of MEHP is 278 g/mole, the UCs are given as 1.5*10 À8 moles/l for both males and females. In a study on the frequency of urination for adults, Van Haarst et al. (2004) reported on void frequencies and volumes for 1152 men and women over age 20. They found that the daily void volumes for men and women were 1.718 and 1.762 l, respectively (the specific number of men and women were not provided). Assuming mean body weights for men and women as 78.1 and 65.4 kg, respectively (EPA, 1997), UVs for men and women are 0.022 and 0.027 l/kg per day, respectively. Using all of these values in Eq. (3) results in a DI for males of 1.76 and 2.16 mg/kg per day for females. Further estimates of a central tendency background intake for Americans are provided in David (2000) and Kohn et al. (2000) . They used NHANES data in Blount et al. (2000) , in combination with creatinine correction approaches similar, though not identical, to Eq. (2) above. David (2000) arrives at a median DEHP intake of 0.60 mg/kg per day, and Kohn et al. (2000) arrives at a similar median intake level of 0.71 mg/kg per day.
In summary, these analyses suggest central tendency estimates of an intake dose of DEHP ranging from 0.6 to 2.2 mg/ kg per day. For the purposes of the following background exercise, a daily intake dose of 1.5 mg/kg per day will be assumed. Because of the linearity of model response, any other daily total can be assumed and the presented results of the model runs can be calculated as the ratio of a different daily intake and 1.5 mg/kg per day, assuming a similar exposure pattern.
The strategy to simulate background exposures to DEHP will be similar to that done earlier for perchlorate by Lorber (2008b) . Specifically, Lorber (2008b) had obtained daily urinary total volumes and times of urinary for several individuals who had been dosed with perchlorate in a study to evaluate the impacts of perchlorate exposure. Similar to the modeling exercise in this paper, a model was calibrated to predict perchlorate excretions in urine and then applied to a background scenario. Lorber used 8 of these individuals who had been dosed, and each had about 7 complete days of urination resulting in 57 complete days of urinations totaling 271 urination events. The patterns of urination in this constructed background cohort were: 4.7 urinations/day (range of 2-7) an average individual void volume of 0.37 l an average daily total voiding of 1.73 l.
This group does not represent the ideal background cohort for at least the following two important reasons: (1) there were only eight individuals and obviously this cohort does not span the range of individuals with regard to age, sex, ethnicity, or other important facets that control volumes and frequencies of urination for a general population, and (2) even for these individuals, their urination pattern may have been influenced by the ingestion of 100 ml of water at the four perchlorate dosing times during the day. Still, the average daily void volume of 1.73 l is similar to the large scale study noted above where the average void volume was 1.72 l for men and 1.76 l for women.
In the modeled DEHP background scenario, individuals will be dosed five times during the day at 0900, 1200, 1500, 1800, and 2100 h at equal amounts of 0.3 mg/kg per day. Besides being uniformly spread out over the day, another purpose of this dosing schedule is that it makes the cohort urination events before 9 am, specifically in the time frame of 4 am to 8 am, the first morning voids, where it can be known that the individual was not exposed after 9 pm the previous evening. The amount of DEHP dose is instantaneously mixed into blood and then simulated to metabolize and add mass of metabolite to each of the reservoirs maintained in the model. The results of this exercise are shown in Table 2 . The mean daily concentration of the three metabolites are 4.6, 15.9, and 9.4 mg/l for MEHP, 5OH-MEHP, and 5oxo-MEHP, respectively, which is close to the medians from the NHANES 2001/02 survey results of 4.1, 20.1, and 14.0 mg/l for the three metabolites. This suggests credibility for the selection of 1.5 mg/kg per day as a representative background exposure estimate for DEHP and also for the empirical backcalculation methods used above, which started from the NHANES 2001/02 measurements of MEHP to arrive at estimated doses of DEHP in the range of 0.6-2.2 mg/kg per day. However, there appears to be a small The daily exposure to DEHP in this background scenario was 1.5 mg/ kg per day, in equal doses of 0.3 mg/kg per day at 0900, 1200, 1500, 1800, and 2100 h. Simple pharmacokinetic model to characterize exposure of Americans to DEHP Lorber et al. but noticeable disparity in predictions of the two secondary metabolites, 5OH-MEHP and 5oxo-MEHP. They are lower than NHANES measurements by about a factor of 0.7. Also, the ratio of concentrations between the secondary metabolites and the primary monoester metabolites is different in the measurements as compared with the modeled ratios. The NHANES measurements suggest a ratio of about 4.9 for 5OH-MEHP to MEHP and a ratio of 3.4 for 5oxo-MEHP to MEHP, but the modeled corresponding ratios are 3.5 and 2.0. This difference merits further examination. First, the model behaved as calibrated. The ratios of the final average concentrations for the individual whose data were used to calibrate the model were the following: 5OH-MEHP to MEHP was 3.4 (derived as average observed 5OH-MEHP of 2.16 mg/l divided by average observed MEHP of 0.63 mg/l over 24 urination events), and 5oxo-MEHP to MEHP was 2.0 (1.29 mg/l divided by 0.63 mg/l). The fact that this individual's ratios were this way could be a function of his age and personal metabolism. As an older individual, age 61 at the time of the experiment, it is possible that he could not metabolize DEHP as completely as would a younger individual. The NHANES data support the observation that age could very well play a role in DEHP metabolism. The following shows the median concentrations of the three metabolites as a function of age (CDC, 2005;  concentrations in mg/l):
Although the MEHP concentrations are highly comparable between the age groups, it certainly appears as though the concentrations of the oxidized metabolites decline with age, and it is possible that by age 61, they would be lower still and be very close to what the model predicted: 15.9 and 9.4 mg/l.
Another possible explanation relates to the time of exposure to DEHP in relation to the time of metabolite measurement in urine. It stands to reason that with MEHP as the first metabolite, it would show up in the higher concentrations near the time of exposure as compared with further away, whereas the secondary metabolites might tend to increase in concentration in urine while the primary metabolite was declining. This was the argument put forth by Barr et al. (2003) , who advocated the analysis of secondary metabolites of phthalates as the primary metabolites may disappear when urine samples were taken, whereas the secondary metabolites would still be present and be evidence of past exposure. The calibration data bore this trend outFthe ratios of 5OH-MEHP to MEHP were 1.7, 1.8, and 3.7 for the first three urination events that occurred within 3 h of the dose taken by the 61-year-old individual. After that, the ratios were mostly above 5.0 (although there were two events at around 8 h post exposure when the ratios were below 3.5), rising to well over 10.0 once MEHP cleared the body at about 20 h. The same trend was noted for 5oxo-MEHP to MEHP: the ratios were 0.9, 1.2, and 2.3 for the first three urinations within 3 h and mostly above 2.5 thereafter. The model simulations of background conditions showed a trend with time of exposure. As derived from the data in Table 2 and given a final dose at 9 pm, the ratios of 5OH-MEHP to MEHP for the urination events at 12 am-4 am and 4 am-8 am were 4.5 and 5.3, respectively, while after that when exposure began again at 9 am, the ratios were more nearly 3.0. A similar trend is seen for the ratio of 5oxo-MEHP to MEHP.
The question is, what is the relationship between when exposure occurred and when urine samples were taken in NHANES? Obviously, this cannot be known for the individual samples in NHANES. However, if the trend in the modeled background scenario is generally true F that morning ratios are higher because predominantly the exposures occurred the previous evening F than it might be noteworthy if the majority of samples from NHANES were taken in the morning. There is some information on the time when the NHANES individuals provided a urine sample. According to the NHANES data sets and the parameter titled, ''PHDSESN,'' which is the time when all examinations occurred, 4792 examinations occurred in the ''morning,'' 3503 examinations occurred in the ''afternoon,'' and 1633 examinations occurred in the ''evenings'' for the 2001/02 data set (data are available at http://www.cdc.gov/ nchs/about/major/nhanes/nhanes01-02.htm). Not all of these examinations involved taking a urine sample that was evaluated for phthalates, but assuming a similar trend for the urine samples measured for phthalates, 46% of the urine samples occurred in the morning hours, the most of the three time slots. Still, if the modeled background scenario is a good reflection of reality, then afternoon and evening concentrations and metabolite ratios are similar to each other (and dissimilar from morning concentrations and ratios) because exposure occurs throughout the day starting at 9 am. Therefore, this data from NHANES on timing of examination, while interesting, does not appear to shed light on the question of ratios of metabolites.
Whether the model results differ slightly from NHANES results because of age/metabolism, or time from last exposure, it is still concluded that the calibrated model in this paper appears to have the capability of predicting DEHP metabolites in a valid mannerFvalid to the point that the model can be used to study trends in DEHP exposures. The hypothetical background exposure scenario assumed equal exposures throughout the day, starting at 9 am and concluding at 9 pm. However, this was not based on any Simple pharmacokinetic model to characterize exposure of Americans to DEHP Lorber et al. specific knowledge of DEHP daily exposureFthis would be and has been the subject of different studies (see Wormuth et al., 2006) . But assuming that the modeled daily exposure regime is a reasonable starting point for study, one can make some observations. It is seen in Table 2 , for example, that the average concentration of MEHP between 12 am and 8 am in the morning is nearly half the daily average concentration. This might call into question about the conclusions of studies using first morning voids only instead of sampling at random times during the day. For example, Koch et al. (2004) report on results of MEHP sampling of school children who had been specifically instructed to provide first morning voids prior to going to school. Their extrapolation to DEHP daily exposures might be low by about one half. Koch et al. (2003a) similarly took first morning samples from 85 ''general population'' individuals (age range, 7-64 years) and extrapolated back to daily DEHP exposure using Eq. (2) above, and similarly, their estimates may be low. Afternoon and evening samples were nearly 50% higher than the daily average, so an issue of representativeness could occur with samples collecting only in the late afternoon and evening. Clearly, the best design of a urine sampling study, given this general dosing regime at least, would be random samples throughout the day.
What is also noteworthy is the difference in trends between the simulations of DEHP exposure in this paper and the simulations of perchlorate that were conducted using the same background cohort and exposure regime (5 times/day at regular hours) and a very similar pharmacokinetic model (Lorber, 2008b) . Unlike MEHP, the perchlorate concentrations in the 4 am to 8 am slots were just as high as afternoon concentrations. It is only after the first morning void that perchlorate concentrations decline to the lowest levels of the day. This pattern results from the dissipation rates calibrated for perchlorate modeling. Specifically, perchlorate dissipates from the blood reservoir into the bladder reservoir at a rate corresponding to a half-life of 7.5 h. Therefore, the afternoon and, in particular, the evening doses of perchlorate are still dissipating into the bladder well into the night and into the morning hours. In contrast, DEHP metabolizes to MEHP very rapidly, with a half-life of 15 min, and then MEHP dissipates rapidly as well to other metabolites and to the bladder reservoir, with a half-life of 2 h. This results in an overall dissipation into the bladder awaiting urination of less than 3.0 h, and most MEHP is excreted before midnight in the model. Unlike perchlorate, and not surprising when taking elimination kinetics into account, the lowest concentrations of MEHP are found in the first morning voids.
Discussion and conclusions
A simple pharmacokinetic model was developed that predicted the concentrations of five metabolites of DEHP in serum and urine. In more detail, this forward-based simulation model runs on a 15-min time step and takes a daily regimen of intakes and predicts serum and urine concentrations over time. This model was calibrated on a data set from a single individual. Then, the model was applied twice to different situationsFonce to a set of data on blood donors and a second relating to background US exposures. The application to the blood donors involved data on 12 individuals whose exposure was due to tubing used in an apheresis procedure to donate blood components. The background application involved constructing a cohort of 8 individuals encompassing 57 days of urinations. A possible range of a central tendency (e.g., median) background total daily intake dose of DEHP was generated using creatininecorrected and urine-volume corrected approaches, in conjunction with NHANES urine data. This range was 0.6-2.2 mg/kg/day. A mid-range estimate of DEHP exposure of 1.5 mg/kg per day was selected from this backcalculated range, and the background cohort was assumed to be exposed to this daily total with individual intakes at one-fifth the daily total at 0900, 1200, 1500, 1800, and 2100 h. The average predicted concentrations were judged as acceptably matching the NHANES median concentrations. This latter exercise provides a dual verification of the backcalculation approaches to estimating intake dose from spot urine sampling, as well as the fact that a MEHP urine concentration of about 4 mg/l corresponds to an intake dose near 1.5 mg/kg/day of DEHP.
This ''dual verification'' of the backcalculation creatininebased and urine volume-based approaches is a non-trivial finding of this work. The model developed in this study is a forward simulation model that was calibrated using data including a known dose of DEHP and the observed concentrations of DEHP metabolites in the subject's serum and urine. The model was then used in an exercise in which the dose was not knownFa general study of background exposures knowing only concentrations in urine. The model could have been applied in a trial-and-error basis to find the intake doses that predicted the measured concentrations in these populations. However, the backcalculation models allow for a ''first estimate,'' if you will, of what the dose might have been for the blood donors and the general US population. It is noteworthy that these first estimates in fact led to forward simulated concentrations that matched the starting point urine concentrations. Without verification, these creatinine-and urine volume-based approaches have been taken on faith and assumptions, but now there is the verification in this paper that they have merit, at least for DEHP.
The modeling approach and findings in this paper can be used to further study patterns of exposure within a population. Modeling a background population in this paper allowed for an examination of daily trends in overall concentration and the ratio of the secondary metabolites to the primary metabolite of DEHP. Another possible study that this model could be used for is a study on elevated exposures of DEHP. For example, the 95th percentile concentration of MEHP found in NHANES 2001/02 data set was 38.9 mg/l. Using the backcalculation approaches based on creatinine would assume that this concentration from a spot sample is typical for the entire day, when in fact that may not be the case. It could be the result of an exposure that happened just a few minutes to a few hours ago, or of course, it could be representative of an ongoing pattern of elevated exposures. Further information on this sample, such as what time of day it was taken, could be studied with the model. If they were first morning voids, they may suggest a possible timing of exposure several hours earlier rather than minutes earlier. The ratio of the metabolite concentrations, if they were taken, could shed further light on the timing and magnitude of the parent phthalate exposure, and these issues could be further studied with the model.
The overall approach in this study can be applied to other phthalates, and indeed other contaminants with similar properties and data sets. For example, Koch and Angerer (2007) developed a data set for DINP analogous to the one they developed for DEHP: they dosed a single individual with 1.27 mg/kg per day of deuterium-labeled DINP and measured three oxidized metabolites (which accounted for approximately 40% of the oral dose) and the simple monoester MINP (which was nearly negligible and accounted for only 2%). With the right data, compounds such as pesticides, which are metabolized and excreted in urine, can be studied in the same manner. The analysis in this paper has also shown why the design of a urine sampling program is important. Ideally, samples should be taken at random times of the day and even at night to provide a proper daily average concentrations. Studies that seek a first morning void, for convenience or for purposes of analysis of other urine constituents, can underestimate average daily urine concentrations for contaminants that rapidly dissipate from the body, such as DEHP.
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